Post-earnings recap
Reported
Wed, May 11, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Edgewise Therapeutics is still in a developmental phase, with losses continuing as expected. The stock's decline of 3.81% reflects investor disappointment over the missed EPS and lack of revenue details. Without guidance, investors may feel uncertain about the company's near-term prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | -4.53% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on advancing its clinical programs despite the current financial results.